Literature DB >> 25052481

TYROBP in Alzheimer's disease.

Jing Ma1, Teng Jiang, Lan Tan, Jin-Tai Yu.   

Abstract

Recently, studies have provided convincing data that TYRO protein tyrosine kinase-binding protein (TYROBP), a key regulator in immune systems, is significantly upregulated in the brain of patients with Alzheimer's disease (AD). TYROBP acts as a signaling adaptor protein for numerous cell surface receptors, playing important roles in signal transduction in dendritic cells, osteoclasts, macrophages, and microglia. Although several TYROBP-related cell surface receptors including triggering receptor expressed on myeloid 2 (TREM2), signal regulatory protein β1 (SIRPβ1), and complement receptor 3 (CR3) were found to participate in the pathogenesis of AD, the role of TYROBP in AD still remains elusive. Emerging piece of evidence has demonstrated that TYROBP could enhance phagocytic activity of microglia, which is responsible for the clearance of amyloid-β (Aβ) peptides and apoptotic neurons. TYROBP also participates in suppression of inflammatory responses by repression of microglia-mediated cytokine production and secretion. In this article, we introduce the structure, localization, and function of TYROBP. Meanwhile, we review recent articles concerning the association of TYROBP and its related receptors with AD pathogenesis and speculate the possible roles of TYROBP in this disease. Based on the potential protective actions of TYROBP in AD pathogenesis, targeting TYROBP might provide new opportunities for AD treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25052481     DOI: 10.1007/s12035-014-8811-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  54 in total

Review 1.  Novel disease-modifying therapies for Alzheimer's disease.

Authors:  Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  DAP12 signaling: from immune cells to bone modeling and brain myelination.

Authors:  Marco Colonna
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 3.  Molecular networks as sensors and drivers of common human diseases.

Authors:  Eric E Schadt
Journal:  Nature       Date:  2009-09-10       Impact factor: 49.962

4.  Variant TREM2 as risk factor for Alzheimer's disease.

Authors:  Harald Neumann; Mark J Daly
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

Review 5.  KARAP/DAP12/TYROBP: three names and a multiplicity of biological functions.

Authors:  Elena Tomasello; Eric Vivier
Journal:  Eur J Immunol       Date:  2005-06       Impact factor: 5.532

6.  Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS.

Authors:  Anna Kiialainen; Karine Hovanes; Juha Paloneva; Outi Kopra; Leena Peltonen
Journal:  Neurobiol Dis       Date:  2005-03       Impact factor: 5.996

7.  Cutting edge: TREM-2 attenuates macrophage activation.

Authors:  Isaiah R Turnbull; Susan Gilfillan; Marina Cella; Taiki Aoshi; Mark Miller; Laura Piccio; Maristela Hernandez; Marco Colonna
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

8.  Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease.

Authors:  Benoit Melchior; Angie E Garcia; Bor-Kai Hsiung; Katherine M Lo; Jonathan M Doose; J Cameron Thrash; Anna K Stalder; Matthias Staufenbiel; Harald Neumann; Monica J Carson
Journal:  ASN Neuro       Date:  2010-07-12       Impact factor: 4.146

9.  A physical interaction between the adaptor proteins DOK3 and DAP12 is required to inhibit lipopolysaccharide signaling in macrophages.

Authors:  Qisheng Peng; Courtney L Long; Shikha Malhotra; Mary Beth Humphrey
Journal:  Sci Signal       Date:  2013-08-20       Impact factor: 8.192

10.  Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals.

Authors:  Jin-Tai Yu; Teng Jiang; Ying-Li Wang; Hui-Fu Wang; Wei Zhang; Nan Hu; Lin Tan; Lei Sun; Meng-Shan Tan; Xi-Chen Zhu; Lan Tan
Journal:  Neurobiol Aging       Date:  2013-10-11       Impact factor: 4.673

View more
  35 in total

1.  Prioritizing network communities.

Authors:  Marinka Zitnik; Rok Sosič; Jure Leskovec
Journal:  Nat Commun       Date:  2018-06-29       Impact factor: 14.919

Review 2.  Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk.

Authors:  Amanda McQuade; Mathew Blurton-Jones
Journal:  J Mol Biol       Date:  2019-02-07       Impact factor: 5.469

3.  TREM2 Ameliorates Neuronal Tau Pathology Through Suppression of Microglial Inflammatory Response.

Authors:  Teng Jiang; Ying-Dong Zhang; Qing Gao; Zhou Ou; Peng-Yu Gong; Jian-Quan Shi; Liang Wu; Jun-Shan Zhou
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

4.  TREM2 Overexpression has No Improvement on Neuropathology and Cognitive Impairment in Aging APPswe/PS1dE9 Mice.

Authors:  Teng Jiang; Yu Wan; Ying-Dong Zhang; Jun-Shan Zhou; Qing Gao; Xi-Chen Zhu; Jian-Quan Shi; Huan Lu; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-01-16       Impact factor: 5.590

5.  RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.

Authors:  Iliya Lefterov; Jonathan Schug; Anais Mounier; Kyong Nyon Nam; Nicholas F Fitz; Radosveta Koldamova
Journal:  Neurobiol Dis       Date:  2015-06-10       Impact factor: 5.996

Review 6.  New insights into macrophage subsets in atherosclerosis.

Authors:  Yurong Wang; Qiong Wang; Danyan Xu
Journal:  J Mol Med (Berl)       Date:  2022-08-05       Impact factor: 5.606

7.  Bioinformatics investigation of therapeutic mechanisms of Xuesaitong capsule treating ischemic cerebrovascular rat model with comparative transcriptome analysis.

Authors:  Jiangquan Liao; Benjun Wei; Hengwen Chen; Yongmei Liu; Jie Wang
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

8.  TYROBP genetic variants in early-onset Alzheimer's disease.

Authors:  Cyril Pottier; Thomas A Ravenscroft; Patricia H Brown; NiCole A Finch; Matt Baker; Meeia Parsons; Yan W Asmann; Yingxue Ren; Elizabeth Christopher; Denise Levitch; Marka van Blitterswijk; Carlos Cruchaga; Dominique Campion; Gaël Nicolas; Anne-Claire Richard; Rita Guerreiro; Jose T Bras; Stephan Zuchner; Michael A Gonzalez; Guojun Bu; Steven Younkin; David S Knopman; Keith A Josephs; Joseph E Parisi; Ronald C Petersen; Nilüfer Ertekin-Taner; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2016-08-08       Impact factor: 4.673

9.  Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis.

Authors:  Young Ho Park; Angela Hodges; Shannon L Risacher; Kuang Lin; Jae-Won Jang; Soyeon Ahn; SangYun Kim; Simon Lovestone; Andrew Simmons; Michael W Weiner; Andrew J Saykin; Kwangsik Nho
Journal:  Neurobiol Aging       Date:  2019-12-10       Impact factor: 4.673

10.  Mutations in TYROBP are not a common cause of dementia in a Turkish cohort.

Authors:  Lee Darwent; Susana Carmona; Ebba Lohmann; Gamze Guven; Celia Kun-Rodrigues; Basar Bilgic; Hasmet Hanagasi; Hakan Gurvit; Nihan Erginel-Unaltuna; Meltem Pak; John Hardy; Andrew Singleton; Jose Brás; Rita Guerreiro
Journal:  Neurobiol Aging       Date:  2017-06-28       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.